Clinical Sitero And CRIO Join Hands to Streamline Clinical Trial...

Sitero And CRIO Join Hands to Streamline Clinical Trial Data


Florida-based CRO Sitero is teaming up with healthcare technology company CRIO to help streamline clinical research for sites and sponsors and enhance patient safety and overall experience.

With more than 100 clients and locations in the U.S., U.K. and India, Sitero has quickly emerged as a frontrunner in the field of clinical services for the life sciences industry. The firm has worked in a wide variety of therapeutic areas, and it excels at offering cutting-edge, tech-enabled solutions that free up its clients’ time and energy to focus on what they do best.

A pioneer in eSource technology, CRIO’s goal is to accelerate the discovery and development of new pharmaceuticals through the simplification of clinical research. The company has developed a comprehensive paperless platform that speeds up timelines, decreases the likelihood of errors, and improves the efficiency of regulatory workflows. 

Both firms, like many others in their industry, are collaborating to use digital innovations in response to the need for more decentralized clinical trials as a consequence of the pandemic. This will be accomplished by automating previously manual, redundant, and error-prone processes throughout the clinical lifecycle.

As a result of the collaboration, previously necessary manual and error-prone tasks across the clinical lifecycle will be rendered obsolete, completely revolutionizing trial execution. 

Through a model that reinvents the conventional approach to conducting clinical research, the two companies will pool their complementary strengths in this venture. CRIO will aim to make the best use of its proprietary technology platform, while Sitero will tap into its deep reserves of clinical expertise to launch a delivery model capable of handling key tasks like data management and monitoring. 

By working together to create a service that is fully integrated with CRIO’s ability to gather and oversee data electronically, the two organizations will be able to cut down on duplication and become able to monitor trials effectively worldwide.

Sankeh Abbhi, CEO of Sitero, stated, “Our unified solution will allow us to execute our trials more efficiently and allow us to be a strategic partner to CRIO’s site customers by providing data entry, query resolution and administrative support services that aim to free up research teams to focus on critical, value-added activities so they can bring treatments to market faster.”

Through this partnership, sponsors and sites will be able to oversee each and every aspect of the clinical trial process remotely as well as electronically. These aspects include, but are not limited to, patient scheduling and stipends, recruitment and IBC services.

Through a user-friendly, all-in-one software platform, users will be able to seamlessly monitor and manage these processes. As a result, research teams will be able to focus on more critical tasks, since they’ll no longer have to manage redundant activities that usually take up so much of their time.

The CEO and co-founder of CRIO, Raymond Nomizu, was delighted at the strategic partnership. He said that it’s high time sponsors and sites got a solution to help them manage critical aspects of the clinical trial process. As such, the partnership will open up amazing possibilities for everyone involved.

+ posts

Latest news

Revvity introduces advanced preclinical imaging tech for scientists to make breakthroughs

Revvity, Inc. is ushering in a new era of innovation in the realm of preclinical research by...

European Commission Approves Updated Pfizer-BioNTech Vaccine for Omicron XBB.1.5 Variant

The European Commission has recently achieved a significant milestone in the ongoing battle against COVID-19 in preparation...

NICE gives Chiesi’s Elfabrio go ahead

Chiesi has recently garnered a favorable recommendation from the National Institute for Health and Care Excellence (NICE)...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you